文献速递产科

预防性甲基麦角新碱联合缩宫素与单用缩宫素在产时剖宫产患者中的比较:一项随机对照试验

Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Patients Undergoing Intrapartum Cesarean Birth: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2022-07-06

这项单中心、安慰剂对照随机试验纳入产时剖宫产患者,比较缩宫素联合甲基麦角新碱与单用缩宫素的效果。联合组需要额外宫缩剂的比例为20%,单用组为55%(RR 0.4,95%CI 0.2-0.6)。联合组产后出血发生率更低(35% vs 59%,RR 0.6,95%CI 0.4-0.9),定量失血量更少(967 mL vs 1,315 mL,均差348,95%CI 124-572),输血频率更低(5% vs 23%,RR 0.2,95%CI 0.1-0.6)。

要点

  • 产时剖宫产预防性加用甲基麦角新碱可减少额外宫缩剂需求(20% vs 55%,RR 0.4)。
  • 联合组子宫张力满意率更高(80% vs 41%,RR 1.9,95%CI 1.5-2.6)。
  • 联合组产后出血(35% vs 59%)和输血(5% vs 23%)频率更低。

核心结论

  • 在产时剖宫产患者中,预防性给予甲基麦角新碱联合缩宫素可减少额外宫缩剂的需求。

研究设计与样本

  • 单中心、安慰剂对照、随机试验,纳入产时剖宫产患者。
  • 患者随机接受静脉缩宫素300 mL/分钟联合肌内甲基麦角新碱0.2 mg(1 mL)或静脉缩宫素300 mL/分钟联合肌内生理盐水(1 mL)。
  • 主要结局为接受额外宫缩剂;次要结局包括外科医生对子宫张力的评估、产后出血发生率、定量失血量和输血。
  • 为检测额外宫缩剂需求的两倍下降(假设基线42%),双侧1型错误5%、把握度80%,每组需样本量76例。
  • 2019年6月至2021年2月,80例随机分至甲基麦角新碱联合缩宫素组,80例随机分至单用缩宫素组。

主要发现

  • 甲基麦角新碱组接受额外宫缩剂的患者显著更少(20% vs 55%,相对危险度[RR] 0.4,95%CI 0.2-0.6)。
  • 甲基麦角新碱组子宫张力满意率更高(80% vs 41%,RR 1.9,95%CI 1.5-2.6)。
  • 甲基麦角新碱组产后出血发生率更低(35% vs 59%,RR 0.6,95%CI 0.4-0.9)。
  • 甲基麦角新碱组平均定量失血量更低(967 mL vs 1,315 mL;均差348,95%CI 124-572)。
  • 甲基麦角新碱组输血频率更低(5% vs 23%,RR 0.2,95%CI 0.1-0.6)。

关键数值与推荐

  • 主要结局额外宫缩剂需求:甲基麦角新碱组20% vs 单用缩宫素组55%,RR 0.4(95%CI 0.2-0.6)。
  • 子宫张力满意:甲基麦角新碱组80% vs 单用缩宫素组41%,RR 1.9(95%CI 1.5-2.6)。
  • 产后出血:甲基麦角新碱组35% vs 单用缩宫素组59%,RR 0.6(95%CI 0.4-0.9)。
  • 定量失血量:甲基麦角新碱组967 mL vs 单用缩宫素组1,315 mL,均差348(95%CI 124-572)。
  • 输血:甲基麦角新碱组5% vs 单用缩宫素组23%,RR 0.2(95%CI 0.1-0.6)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the administration of prophylactic methylergonovine in addition to oxytocin in patients undergoing intrapartum cesarean birth reduces the need for additional uterotonic agents. METHODS: This was a single-center, placebo-controlled, randomized trial of patients undergoing intrapartum cesarean birth. Patients were randomly allocated to receive intravenous oxytocin 300 mL/minute plus intramuscular methylergonovine 0.2 mg (1 mL) or intravenous oxytocin 300 mL/minute plus intramuscular normal saline (1 mL). The primary outcome was the receipt of additional uterotonic agents. Secondary outcomes included surgeon assessment of uterine tone, incidence of postpartum hemorrhage, quantitative blood loss, and blood transfusion. To detect a twofold decrease in the need for additional uterotonic agents (assuming a 42% baseline) with a two-sided type 1 error of 5% and power of 80%, a sample size of 76 patients per group was required. RESULTS: From June 2019 through February 2021, 80 patients were randomized to receive methylergonovine plus oxytocin and 80 were randomized to receive to oxytocin alone. Significantly fewer patients who were allocated to the methylergonovine group received additional uterotonic agents (20% vs 55%, relative risk [RR] 0.4, 95% CI 0.2-0.6). Participants receiving methylergonovine were more likely to have satisfactory uterine tone (80% vs 41%, RR 1.9, 95% CI 1.5-2.6), lower incidence of postpartum hemorrhage (35% vs 59%, RR 0.6, 95% CI 0.4-0.9), lower mean quantitative blood loss (967 mL vs 1,315 mL; mean difference 348, 95% CI 124-572), and a lower frequency of blood transfusion (5% vs 23%, RR 0.2, 95% CI 0.1-0.6). CONCLUSION: The administration of prophylactic methylergonovine in addition to oxytocin in patients undergoing intrapartum cesarean birth reduces the need for additional uterotonic agents. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03904446.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Masse N, Dexter F, Wong CA, et al. Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Patients Undergoing Intrapartum Cesarean Birth: A Randomized Controlled Trial. Obstet Gynecol. 2022. PMID: 35852267. doi:10.1097/AOG.0000000000004857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。